Merxin Ltd and OECHSLERhealth are excited to announce a Strategic Partnership to Establish The SMI PowerHouse to Streamline Soft Mist Inhaler Access for Drug Developers.
King’s Lynn, Norfolk, U.K.; Ansbach, Bayern, Deutschland – 10 December 2024.
Merxin Ltd, an innovative designer and supplier of inhalers and OECHSLERhealth, a leading Contract Manufacturing Organization (CMO) for medical devices are excited to announce a strategic partnership to establish The SMI PowerHouse, a transformative venture aimed at streamlining and widening access to Soft Mist Inhalers (SMIs) and accelerating the path to market for Drug Developers.
This collaboration started in 2018 leverages OECHSLERhealth’s manufacturing and assembly expertise alongside Merxin Ltd’s proprietary MRX004 SMI advanced design and unrivalled market access, setting new standards for I.P protection, performance, reliability, speed, and cost-effectiveness in the inhaler industry.
Key Benefits for Drug Developers
Through The SMI Powerhouse, Merxin Ltd and OECHSLERhealth will empower inhaled drug developers with faster access to market-ready SMI devices by addressing key enablers. The Strategic Partnership is designed to:
• Reduce Time to Market: Clients will bypass upfront device investments, gaining near-immediate access to advanced inhaler solutions. With pre-established manufacturing processes in place, drug developers will expedite the start of clinical trials and series production timelines.
• Enhance Reliability: The partnership prioritizes ISO-certified design and manufacturing processes that ensure consistent quality and availability, supporting Clients in meeting crucial development milestones with confidence. It creates a robust device access path that instils confidence in Investors and Developers.
• Widen Access to Superior Drug Delivery: MRX004 SMI ensures deep lung deposition thanks to its slow velocity plume and fine droplet size distribution. Developed as an easy-to-use inhaler with no dose handling and 4 simple steps, it delivers up to 300 doses with an integrated dose counter. MRX004 is covered by Merxin Ltd proprietary I.P.
• Optimize Costs: By utilizing Merxin Ltd’s MRX004 SMI technology and OECHSLERhealth’s efficient production framework, Clients benefit from minimized investment requirements, supporting rapid scaling without compromising quality.
Together, Merxin Ltd and OECHSLERhealth will become the leading supplier of SMIs, providing drug developers with a platform to succeed in their markets and to enhance patient outcomes worldwide.
“This partnership with OECHSLERhealth is hugely exciting. It brings to life our vision for The SMI Powerhouse, enabling quicker and more reliable access to market-ready SMIs while maintaining our focus on patient care and environmental stewardship,” stated Philippe Rogueda, CBO of Merxin Ltd.
“This partnership with Merxin Ltd positions us to redefine the value chain of SMIs. Together, we’re raising the bar for accessibility, performance, reliability and innovation, helping our clients bring impactful inhalation therapies to patients faster,” said Felix Hess, Senior Vice President of the Health Business Unit at OECHSLERhealth.
Why Choose MRX004 SMI?
MRX004 SMI is a revolutionary advancement in inhaled drug technology. Specifically designed for deep lung deposition and ease of use, our multidose soft mist inhaler accommodates liquid formulations. By leveraging mechanical energy, MRX004 creates a fine, slow-moving aerosol without relying on propellants or electric power, making i t an environmentally friendly choice with a low carbon footprint that can be used with low global warming potential formulations. MRX004 isn’t just another medical device; it’s your partner in pioneering new therapies and patient care. With our commitment to innovation and integrity, we help you unlock the potential of your next groundbreaking product. Together, let’s elevate the standards of lung delivery.
About Merxin Ltd
We Make Inhalers. We design and supply dry powder and soft mist inhalers for clinical evaluation through to commercial supply. Our expertise encompasses various therapeutic categories, from biologics and small molecules to generic and novel therapies. We work closely with our customers to provide inhaler devices tailored for their drug formulations, ensuring effective final dosage forms for users and patients. Our DNA is in the pharma industry. Merxin Ltd is committed to delivering quality, reliability, and efficacy, our reputation is built on excellence; We Will Launch You. As experts in oral inhaled delivery, we are committed to advancing respiratory healthcare. We Make It Better.
For more information visit https://www.merxin.com/
and follow us on LinkedIn https://www.linkedin.com/company/merxin-ltd
For more information, contact: info@merxin.com
About OECHSLERhealth
OECHSLERhealth is the dedicated healthcare business unit of OECHSLER Group, a leader in advanced plastics technology, delivering high-quality manufacturing and development services for medical devices and healthcare solutions worldwide. With more than 30 years of expertise spanning from design to series production and ISO-certified quality management, OECHSLERhealth manufactures medical and pharmaceutical devices for their clients.
